

8 Literaturverzeichnis

1. Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ. **Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase**. Science 2001; 291: 2613-2616.
2. Akesson TR, Mantyh PW, Mantyh CR, Matt DW, Micevych PE. **Estrous cyclicity of 125I-cholecystokinin octapeptide binding in the ventromedial hypothalamic nucleus. Evidence for downmodulation by estrogen.** Neuroendocrinology 1987; Apr;45(4): 257-62.
3. Anand BK and Brobeck JR. **Localization of a "feeding center" in hypothalamus of the rat.** Proceedings of the Society for Experimental Biology and Medicine 1951; 77: 323-324.
4. Barrett AM, McSharry L. **Inhibition of drug-induced anorexia in rats by methysergide.** J Pharm Pharmacol. 1975 Dec; 27(12): 889-95.
5. Beinfeld MC. **Cholecystokinin in the central nervous system: a minireview.** Neuropeptides 1983; Oct;3(6): 411-27.
6. Bergmann KE, Mensink GB. **Anthropometric data and obesity.** Gesundheitswesen 1999; 61: 115 – 120.
7. Bickerdike M, Steven P, Vickers, Colin T, Dourish. **5-HT₂- receptor modulation and the treatment of obesity.** Diabetes, Obesity and Metabolism 1999 Jul; 1(4): 207-14.
8. Blundell JE, Latham CJ, Leshem MB. **Biphasic action of a 5-hydroxytryptamine inhibitor on fenfluramine-induced anorexia.** J Pharm Pharmacol. 1973 Jun; 25(6): 492-4.

9. Blundell JE, Latham CJ, Leshem MB. **Differences between the anorexic actions of amphetamine and fenfluramine--possible effects on hunger and satiety.** J Pharm Pharmacol. 1976 Jun; 28(6): 471-7.
10. Blundell JE, Latham CJ. **Serotonergic influences on food intake: effect of 5-hydroxytryptophan on parameters of feeding behaviour in deprived and free-feeding rats.** Pharmacol Biochem Behav. 1979 Oct; 11(4): 431-7.
11. Blundell JE, Lawton CL, Hill AJ., BioPsychology Group, University of Leeds, UK. **Mechanisms of appetite control and their abnormalities in obese patients.** Horm Res. 1993; 39 Suppl 3: 72-6.
12. Blundell JE. **The control of appetite: basic concepts and practical implications.** Schweiz Med Wochenschr. 1999 Feb 6; 129(5): 182-8.
13. Bodansky O. **Clinical applications of biochemistry.** Annu Rev Biochem. 1955; 24: 627-52.
14. Brenner LA and Ritter RC. **Intracerebroventricular cholecystokinin A-receptor antagonist does not reduce satiation by endogenous CCK.** Physiol. Behav. 1998; 63: 711-716.
15. Brobeck JR. **Neural regulation of food intake.** Ann N Y Acad Sci. 1955 Jul 15; 63(1): 44-55.
16. Buffa R, Solcia E, Go VL. **Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa.** Gastroenterology 1976 Apr; 70(4): 528-32.
17. Calam J, Ellis A., Dockray GJ. **Identification and measurement of molecular variants of cholecystokinin in duodenal mucosa and plasma. Diminished concentrations in patients with celiac disease.** J Clin Invest. 1982 Jan; 69(1): 218-25.
18. Clark JT, Kalra PS, Kalra SP. **Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats.** Endocrinology 1985 Dec; 117(6): 2435-42.

19. Clineschmidt BV, Mcguffin JC, Werner AB. **Role of monoamines in the anorexigenic actions of fenfluramine, amphetamine and p-chloromethamphetamine.** Eur J Pharmacol. 1974 Aug; 27(3): 313-23.
20. Cooper SJ. and Dourish CT. **Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding.** Physiol. Behav. 1990a; 48: 849-857.
21. Cooper SJ, Dourish CT, Barber DJ. **Reversal of the anorectic effect of (+) -fenfluramin in the rat by the selectiv cholezystokinin receptor antagonist MK-329.** Br J Pharmacol 1990b; 99: 65-70.
22. Cooper SJ, Dourish CT, Clifton PG. **CCK antagonists and CCK- monoamine interactions in the control of feeding.** Am J Clin Nutr. 1992 Jan; 55 (1Suppl): 291-295S.
23. Cooper SJ. **Cholecystokinin modulation of serotonergic control of feeding behavior.** Ann NY Acad Sci. 1996; 780: 213-222.
24. Corp ES, McQuade J, Moran TH, Smith GP. **Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.** Brain Res. 1993 Sep 24;623(1):161-6.
25. Corp ES, Curcio M, Gibbs J, Smith GP. **The effect of centrally administered CCK-receptor antagonists on food intake in rats.** Physiol. Behav. 1997 Jun; 61(6): 823-7.
26. Curzon G, Gibson EL and Oluyomi AO. **Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.** Trends Pharmacol Sci. 1997; 18: 21-25.
27. Dalton M, Cameron AJ, Zimmer PZ. **Waist circumference, waist-hip-ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults.** JinternMed. 2003; 254: 555-563.

28. Despres JP, Lemieux I, Prud'homme D. **Treatment of obesity: need to focus on high risk abdominally obese patients.** *BMJ* 2001; 322: 1415-1428.
29. Dockray GJ. **Immunochemical evidence of cholecystokinin-like peptides in brain.** *Nature*. 1976 Dec 9; 264(5586): 568-70.
30. Dorre D, Smith GP. **CholecystokininB receptor antagonist increases food intake in rats.** *Physiol. Behav.* 1998 Aug.; 65(1): 11-4.
31. Dourish CT, Hutson PH, Curzon G. **Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT).** *Brain Res Bull.* 1985 Oct; 15(4): 377-84.
32. Dourish CT, Hawley D, Iversen SD. **Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718.** *Eur J Pharmacol.* 1988 Mar 15; 147(3): 469-72.
33. Dourish CT, Rycroft W, Iversen SD. **Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.** *Science.* (1989a) Sep 29; 245(4925): 1509-11.
34. Dourish CT, Ruckert AC, Tattersall FD, Iversen SD. **Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors.** *Eur J Pharmacol.* (1989b) Dec 7; 173(2-3): 233-4.
35. Duhault J, Verdavainne C. **Modification of the cerebral serotonin level in the rat by trifluoromethyl-2-phenyl ethyl aminopropane (Fenfluramine 768 S)** *Arch Int Pharmacodyn Ther.* 1967 Dec; 170(2): 276-86.
36. Duva MA, Tomkins EM, Moranda LM, Kaplan R, Sukhaseum A, Jimenez A, Stanley BG. **Reverse microdialysis of N-methyl-D-aspartic acid into the lateral hypothalamus of rats: effects on feeding and other behaviors.** *Brain Res.* 2001 Dec 7; 921(1-2): 122-32.

37. Ebenezer IS, de la Riva C, Baldwin BA. **Effects of the CCK receptor antagonist MK-329 on food intake in pigs.** *Physiol Behav.* 1990 Jan; 47(1): 145-8.
38. Ebenezer IS and Brooman J. **Pretreatment with the 5-HT_{1A} receptor agonists 8-OH-DPAT or gepirone does not attenuate the inhibitory effect of systemically administered cholecystokinin (CCK) on food intake in rats.** *Methods Find. Exp. Clin. Pharmacol.* 1994, 16: 589-595.
39. Ebenezer IS, Baldwin BA. **2-Naphthalenesulphonyl-L-aspartyl-2-(phenetyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor.** *Br.J Pharmacol.* 1995 Nov; 116(5): 2371-4.
40. Ebenezer IS. **Systemic administration of cholecystokinin (CCK) inhibits operant water intake in rats: implications for the CCK-satiety hypothesis.** *Proc Biol Sci.* 1996 Apr 22;263(1369):491-6.
41. Ebenezer IS. **The effects of a peripherally acting cholecystokinin₁ receptor antagonist on food intake in rats: implications for the cholecystokinin-satiety hypothesis.** *Eur J Pharmacol.* 2003 Feb 14;461(2-3):113-8.
42. Eberle-Wang K., Simansky KJ. **The CCK-A receptor antagonist, devazepide, blocks the anorectic action of CCK but not peripheral serotonin in rats.** *Pharmacol. Biochem. Behav.* 1992; 43: 943-7.
43. Eberlein GA, Eysselein VE, Davis MT, Lee TD, Shively JE, Grandt D, Niebel W, Williams R, Moessner J, Zeeh J, et al. **Patterns of prohormone processing. Order revealed by a new procholecystokinin-derived peptide.** *J Biol Chem.* 1992 Jan 25; 267(3): 1517-21.
44. Elmquist, J.K., Elias, C.F., Saper, C.B. **From Lesions to Leptin: Hypothalamic Control of Food Intake and Body Weight** *Neuron* 1999; 22: 221-232.
45. Emond M, Schwartz GJ, Ladenheim EE, Moran TH. **Central leptin modulates behavioral and neural responsivity to CCK.** *Am J Physiol* 1999; 276: 1545-1549.

46. Eng J, Shiina Y, Straus E, Yalow RS. **Post-translational processing of cholecystokinin in pig brain and gut.** Proc Natl Acad Sci U S A 1982 Oct; 79(19): 6060-4.
47. Ferguston CP. **Are serotonin selektive reuptake inhibitors effektiv in underweight anorexia nervosa?** Int. J. Eating Disord. 1999; 25: 11-17.
48. Flegall KM, Carroll MD, Ogden CL, Johnson CL. **Prevalence and trends in obesity among US adults, 1999-2000.** JAMA 2002; 288: 1723-1727.
49. Freidinger RM. **Cholecystokinin and gastrin antagonists.** Med Res Rev. 1989 Jul-Sep; 9(3): 271-90.
50. Funakoshi,A., Miyasaka,K., Shinozaki,H., Masuda,M., Kawanami,T., Takata,Y. and Kono A. **An animal model of congenital defect of gene expression of cholezystokinin (CCK)-A receptor.** Biochem Biophys Res Commun. 1995; 210: 787-796.
51. Fuxe K, Farnebo LO, Hamberger B, Ogren SO. **On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine.** Postgrad Med J. 1975; 51 Suppl 1:35-45.
52. Gadde KM, Parker CB, Maner LG. **Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.** Obes Res 2001; 9: 544-551.
53. Garlicki,J., Konturek,P.K., Majka,J., Kwiecien,N. and Konturek,S.J. **Cholecystokinin receptors and vagal nerves in control of food intake in rats.** Am. J. Physiol. 1990; 258: E40-E45.
54. Gibbs J, Young RC and Smith G P. **Cholecystokinin decreases food intake in rats.** J Comp Physiol Psychol, 84 (1973) 488-495

55. Glaum SR, Hara M, Bindokas VP, Lee CC, Polonsky KS, Bell GI, Miller RJ. **Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.** Mol Pharmacol. 1996 Aug; 50(2): 230-5.
56. Gleiter CH, Volz HP. **Fluoxetine.** Dtsch Med Wochenschr. 1997 Apr 11; 122(15): 481-482.
57. Goke,B, Printz,H, Koop,I, Rausch,U, Richter,G, Arnold,R, and Adler,G. **Endogenous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate).** Pancreas. 1 (1986) 509-515.
58. Green,GM, Levan,VH, and Liddle,RA. **Interaction of dietary protein and trypsin inhibitor on plasma cholecystokinin and pancreatic growth in rats.** Adv Exp Med Biol, 199 (1986) 123-132.
59. Green GM, Taguchi S, Friestman J, Chey WY, Liddle RA. **Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat.** Am J Physiol. 1989 Jun; 256(6 Pt 1): G1016-21.
60. Grignaschi G, Mantelli B, Fracasso C, Anelli,M, Caccia,S, and Samanin,R, **Reciprocal interaction of 5-hydroxytryptamine and cholecystokinin in the control of feeding patterns in rats,** Br J Pharmacol. 1993, 109: 491-494.
61. GrignaschiG and Samanin,R. **Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat.** Eur J Pharmacol, 212 (1992) 287-289.
62. Gubler U, Chua AO, Hoffman BJ, Collier KJ., Eng J.
Cloned cDNA to cholecystokinin mRNA predicts an identical preprocholecystokinin in pig brain and gut.
Eng J. Proc Natl Acad Sci U S A. 1984 Jul; 81(14): 4307-10.
63. Haleem DJ, Haider S. **Food restriction decreases serotonin and its synthesis rate in the hypothalamus.** Neuroreport. 1996 Apr 26; 7(6): 1153-6.

64. Halford JC, Harrold JA, Lawton CL, Blundell JE. **Serotonin (5-HT) drugs: Effekt on appetite expression and use for the treatment of obesity.** *Curr Drug Targets* 2005 Mar; 6(2): 201-13.
65. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. **Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.** *Drugs*. 2007;67(1):27-55.
66. Haslam DW, James WP. **Obesity.** *Lancet* 2005; 366: 1197-1209.
67. Hayes MR, Savastano DM, Covasa M. **Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT₃ receptors.** *Physiol.Behav.* 2004; 82(4): 663-9.
68. Hayes MR, Covasa M. **CCK and 5-HT act synergistically to suppress food intake through simultaneous activation of CCK-1 and 5-HT₃ receptors.** *Peptides* 2005; 26(11): 2322-30.
69. Hayes MR, Chory FM, Gallagher CA, Covasa M. **Serotonin type-3 receptors mediate cholecystokinin-induced satiation through gastric distension.** *AmJPhysiol Regul Integr Comp Physiol.* 2006 Jul; 291(1):R115-23.
70. Hetherington AW and Ranson SW. **The spontaneous activity and food intake in rats with hypothalamic lesions,** *Am. J. Physiol.*, 136 (1942) 609-617.
71. Hewson G, Leighton GE, Hill RG, Hughes J. **The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin.** *Br J Pharmacol.* 1988 Jan; 93(1):79-84.
72. Hill DR, Shaw TM, Woodruff GN. **Binding sites for 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass.** *Neurosci Lett.* 1988 Jun 29;89(2):133-9.

73. Hoek van der GA, Cooper SJ. **Ondansetron, a selective 5-HT₃ receptor antagonist, reduces palatable food consumption in the nondeprived rat.** *Neuropharmacology*. 1994 Jun; 33(6): 805-11.
74. Hofbauer KG, Nicholson JR. **Pharmacotherapy of obesity.** *Exp Clin Endocrinol Diabetes*. 2006 Oct;114(9):475-84.
75. Holladay MW, Bennett BA, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L and Nadzan AM. **Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo,** *J Med Chem*. 1992, 35: 2920-2928.
76. Hoyer D. **Molecular pharmacology and biology of 5-HT_{1C} receptors.** *Trends Pharmacol Sci*. 1988 Mar; 9(3): 89-94.
77. Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM. **Identification of a 5-HT₁ recognition site in human brain membranes different from 5-HT_{1A}, 5-HT_{1B} and 5-HT_{1C} sites.** *Neurosci Lett*. 1988 Mar 10; 85(3): 357-62.
78. Hoyer D, Hannon JP, Martin GR. **Molecular, pharmacological and functional diversity of 5-HT receptors.** *Pharmacol Biochem Behav*. 2002 Apr;71(4):533-54.
79. Hutson PH, Donohoe TP and Curzon G. **Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia.** *Psychopharmacology (Berl)*, 95 (1988a) 550-552.
80. Jansen JB, Lamers CB. **Molecular forms of cholecystokinin in human plasma during infusion of bombesin.** *Life Sci*. 1983 Nov 28; 33(22): 2197-205.
81. Jorpes JE. **Origin and mode of action of cholecystokinin--pancreozymin** *Verh Dtsch Ges Inn Med*. 1969; 75: 292-6.

82. Kaye WH. **Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa.** Ann. N.Y. Acad. Sci. 1997; 817, 162-178
83. Koenig SM. **Pulmonary complications of obesity.** Am J Med Sci. 2001; 321: 249-279.
84. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. **Brain-gut axis and its role in the control of food intake.** J Physiol Pharmacol. 2004 Mar;55(1 Pt 2):137-54.
85. Kruk ZL. **Dopamine and 5-hydroxytryptamine inhibit feeding in rats.** Nat New Biol. 1973 Nov 14; 246(150): 52-3.
86. Kunitz M. **Crystalline soybean trypsin inhibitor.** J.Gen. Physiol. 1947a; 30: 291-310.
87. Kunitz M. **Isolation of a crystalline protein compound of trypsin and soybean trypsin inhibitor.** J Gen. Physiol. 1947b; 30: 311-320.
88. Kushner RF, Manzano H. **Obesity pharmacology: Past, present, and future.** Curr Opin Gastroent 2002; 18: 213-220.
89. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT . **Abdominal obesity is associated with increased risk of acute coronary events in men.** Eur Heart J 2002; 23: 706-713.
90. Larsson LI, Rehfeld JF. **Localization and molecular heterogeneity of cholecystinin in the central and peripheral nervous system.** Brain Res. 1979 Apr 13; 165(2): 201-18.
91. Lauer MS, Anderson KM, Kanell WB, Levy D. **The impact of obesity on left ventricular mass and geometry.** The Framingham Heart Study 1991; JAMA 266: 231-236.
92. Lean ME, Hant S, Morrison CE. **Waist circumference as a measure for indicating need for weight management.** BMJ 1995; 311: 158-161.

93. Leibowitz SF, Rossakis C. **Mapping study of brain dopamine- and epinephrine-sensitive sites which cause feeding suppression in the rat.** Brain Res. 1979 Aug 17;172(1):101-13.
94. Lesses MF, Myerson A. **Human autonomic pharmacology. XVI. Bensedrine sulfate as an aid in the treatment of obesity. 1938.** Obes Res. 1994 May; 2(3): 286-92. (Comment in:Obes Res. 1994 May;2(3):282-5).
95. Li JY, Finnis S, Yang YK, Zeng Q, Qu SY, Barsh G, Dickinson C, Gantz I. **Agouti-related protein-like immunoreactivity: characterization of release from hypothalamic tissue and presence in serum.** Endocrinology 2000 Jun;141(6): 1942-50.
96. Liddle RA, Goldfine ID, Williams JA. **Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor and alcohol.** Gastroenterology 1984; 87(3): 542-549.
97. Liddle RA, Green GM, Conrad CK, Williams JA. **Proteins but no amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat.** Am J Physiol. 1986 Aug; 251 (2 PT 1): G2 43-8.
98. Lin CW, Holladay MW, Witte DG, Miller TR, Wolfram CAW, Bianchi BR, Bennett MJ and Nadzan AM. **A71378: A CCK agonist with high potency and selectivity for CCK-A receptors,** Am J Physiol. 1990; 258: G648-G651.
99. Lin CW, Miller TR. **Both CCK-A and CCK-B/gastrin receptors are present on rabbit vagus nerve.** Am J Physiol. 1992 Sep; 263(3 Pt 2): R591-5.
100. Linden A, Uvnas-Moberg K, Forsberg G, Bednar I, Sodersten P. **Plasma concentrations of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide.** J Endocrinol. 1989 Apr;121(1):59-65.
101. Loftus TM, Jaworsky DE, Frehywot GL. **Reduced food intake and body weight in mice treated with fatty acid synthase-inhibitors.** Science 2000; 288: 2379-2381.

102. Lopez M, Seoane L, Garcia MC, Lago F, Casanueva FF, Senaris R, Dieguez C. **Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus.** *Biochem Biophys Res Commun.* 2000 Mar 5; 269(1): 41-5.
103. Manson JE, Willett WC, Stampfer MJ. **Body weight and mortality among woman.** *N Engl J Med* 1995; 333: 677-685.
104. Marsden CA, Sleight AJ, Fone KC, Jonson JV, Crespi F, Martin KF, Garrett JC, Bennett GW. **Functional identification of 5HT receptor subtypes.** *Comp Biochem Physiol A.* 1989; 93(1): 107-14.
105. Marsden CA. **The neuropharmacology of serotonin in the central nervous system.** In: Feighner, JP, Boyer WF, (eds.) *Selective serotonin re-uptake inhibitors.* 2nd ed. Wiley, Chichester (1996), pp.1-33.
106. McLaughlin CL, Peikin SR, Baile CA. **Trypsin inhibitor effects on food intake and weight gain in zucker rats.** *Physiol Behav* 1983; 31: 487-91.
107. Mennini T, Bizzi A, Caccia S, Codegoni A, Fracasso C, Frittoli E, Guiso G, Padura IM, Taddei C, Uslenghi A. **Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.** *Naunyn Schmiedebergs Arch Pharmacol.* 1991, 343: 483-490.
108. Mensink, Lampert, Bergmann. **Übergewicht und Adipositas in Deutschland 1984-2003.** *Bundesgesundheitsblatt* 2005; 48: 1348-56
109. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, Trayhurn P. **Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus.** *J Neuroendocrinol.* 1996 Oct; 8(10): 733-5.
110. Miyasaka K, Guan DF, Liddle RA, Green GM. **Feedback regulation by trypsin: evidence for intraluminal CCK-releasing peptide.** *Am J Physiol.* 1989 Aug;257(2 Pt 1):G175-81.

111. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. **Inhibition of gastric inhibitory polypeptide signaling prevents obesity.** Nat Med. 2002 Jul;8(7):738-42. Epub 2002 Jun 17
112. Moran TH, Robinson PH, Goldrich MS, McHugh PR. **Two brain cholecystokinin receptors: implications for behavioral actions.** Brain Res. 1986 Jan 1; 362(1): 175-9.
113. Moran TH, McHugh PR. **Gastric and nongastric mechanisms for satiety action of cholecystokinin.** Am J Physiol. 1988 Apr; 254(4 Pt 2): R628-32.
114. Moran TH, Ameglio PJ, Peyton HJ, Schwartz GJ, McHugh PR. **Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys.** Am J Physiol 1993 Sep; 265 (3 Pt 2): R620-4.
115. Moran TH, Katz L.F, Plata S and Schwartz GJ. **Disordered food intake and obesity in rats lacking cholecystokinin A receptors.** Am J Physiol. 1998, 274: R618-R625.
116. Moran, T.H. **Cholecystokinin and satiety: current perspectives.** Nutrition, 16 (2000) 858-865.
117. Moran TH, Kinzig KP. **Gastrointestinal satiety signals II. Cholecystokinin.** Am J Physiol Gastrointest Liver Physiol. 2004 Feb;286(2):G183-8.
118. Mueller K, Hsiao S. **Specificity of cholecystokinin satiety effect: reduction of food but not water intake.** Pharmacol Biochem Behav. 1977 Jun;6(6):643-6.
119. Munro JF, Seaton DA, Duncan LJ. **Treatment of refractory obesity with fenfluramine.** Br Med J. 1966 Sep 10; 2(514): 624-5.

120. Neill JC, Cooper SJ. **Effects of 5-hydroxytryptamine and d-fenfluramine on sham feeding and sham drinking in the gastric-fistulated rat.** *Physiol Behav.* 1989 Dec; 46(6): 949-53.
121. Opitz K. **Anorexigenic phenylalkylamines and serotonin metabolism.** *Naunyn Schmiedebergs Arch Exp Pathol Pharmacol.* 1967; 259(1): 58-65.
122. Otsuki M, Tani S, Fujii M, Nakanura T, Okabayashi Y, Koide M. **Differential effects of proteinase inhibitor camostat on exocrine pancreas in fed and fasted rats.** *Am.J Physiol.* 1993 Oct., 265 (4Pt2): R 896-901.
123. Pazos A, Cortes R, Palacios JM. **Quantitative receptor autoradiography: application to the characterization of multiple receptor subtypes.** *J Recept Res.* 1984;4(1-6):645-56.
124. Pedigo NW, Yamamura HI, Nelson DL. **Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.** *J Neurochem.* 1981 Jan; 36(1): 220-6.
125. Peroutka SJ, Snyder SH. **Multiple serotonin receptors: differential binding of [3H]5- hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.** *Mol Pharmacol.* 1979 Nov; 16(3): 687-99.
126. Poeschla B., Gibbs J., Simansky K.J. and Smith,G.P. **The 5HT1A agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin.** *Pharmacol Biochem Behav,* 42 (1992) 541-543.
127. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. **Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss.** *Arterioscler Thromb Vasc Biol.* 2006 May;26(5):968-76.
128. Polak JM, Bloom SR, Rayford PL, Pearse AG, Buchan AM, Thompson JC. **Identification of cholecystokinin-secreting cells.** *Lancet.* 1975 Nov 22; 2(7943): 1016-8.

129. Rehfeld JF, Mogensen NW, Bardram L, Hilsted L, Monstein HJ. **Expression, but failing maturation of procholecystokinin in cerebellum.** Brain Res. 1992 Mar 27;576(1):111-9.
130. Reidelberger RD, Varga G, Solomon TE. **Effects of selectiv cholecystokinin antagonists L-365,718 and L 365,260 on food intake in rats.,** Peptides 1991;12:1215.
131. Reidelberger RD, Castellanos DA, Hulce M. **Effects of periphral Receptor Blockade on Food Intake in Rats.** Am J Physiol Regul Integr Comp Physiol. 2003 May 8; 285(2):R429-37.
132. Rodriguez R, Rojas-Ramirez JA, Drucker-Colin RR. **Serotonin-like actions of quipazine on the central nervous system.** Eur J Pharmacol. 1973 Nov; 24(2): 164-71.
133. Rowland NE, Antelman SM, Bartness TJ. **Comparison of the effects of fenfluramine and other anorectic agents in different feeding and drinking paradigms in rats.** Life Sci. 1985 Jun 17; 36(24): 2295-300.
134. Schick RR, Schusdziarra V, Yaksh TL and Go VLW. **Brain regions where cholecystokinin exerts its effect on satiety.** Ann. NY Acad. Sci. 1994; 713: 242-254.
135. Schioth HB, Lagerstrom MC, Watanobe H, Jonsson L, Vergoni AV, Ringholm A, Skarphedinsson JO, Skuladottir GV, Klovins J, Fredriksson R., **Functional role, structure, and evolution of the melanocortin-4 receptor.** Ann N Y Acad Sci. 2003 Jun;994:74-83
136. Schwartz D, Hernandez L, Hoebel BG. **Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis.** Brain Res. 1989 Mar 20; 482(2):261-70.
137. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. **Identification of targets of leptin action in rat hypothalamus.** J Clin Invest. 1996 Sep1; 98(5): 1101-6.

138. Schwartz MW, Porte DJ. **Diabetes, obesity and the brain.** Science 2005; 375-9.
139. Sharara,A.I., Bouras,E.P., Misukonis,M.A., and Liddle,R.A., Evidence for indirect dietary regulation of cholecystokinin release in rats, Am J Physiol, 265 (1993) 107-112
140. Shaskan EG, Snyder SH. **Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake.** J Pharmacol Exp Ther. 1970 Nov; 175(2): 404-18.
141. Silverstone JT, Cooper RM, Begg RR. **A comparative trial of fenfluramine and diethylpropion in obesity.** Br J Clin Pract. 1970 Oct; 24(10): 423-5.
142. Simansy KJ, Vaida AH. **Behavioral mechanisms for the anorectic action of serotonin (5-HT) uptake inhibitor sertraline in rats: Comparison with directly acting 5-HT agonists.** Brain Res Bull 25 1990; 953-60.
143. Simansky KJ: **5-HT receptor subtypes influencing feeding and drinking: Focus on the periphery.** In: Cooper SJ, Clifton PG, editors. Drug receptor Subtypes and Ingestive Behavior. London: Academic press 1996, pp 59-97.
144. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Kempf M. **Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.** European Multicentre Orlistat Study Group.Lancet. 1998 Jul 18; 352(9123): 167-72.
145. Smith G.P, Greenberg D, Falasco J.D., Avilion AA, Gibbs J, Liddle RA and Williams JA. **Endogenous cholecystokinin does not decrease food intake or gastric emptying in fasted rats.** Am J Physiol. 1989; 257: 1462-6.
146. Smith GP, Gibbs J. **Role of CCK in satiety and appetite control.** Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A: 476A.

147. Solcia E, Capella C, Vassallo G, Buffa R. **Endocrine cells of the gastric mucosa.** Int Rev Cytol. 1975; 42: 223-86.
148. Stallone D, Nicolaidis S and Gibbs J, **Cholecystokinin-induced anorexia Depends on serotonergic function.** Am. J. Physiol. 1989; 256: R1138-R1141.
149. Statistisches Bundesamt: **Leben und Arbeiten in Deutschland. Ergebnisse des Mikrozensus 2003.**
http://www.destatis.de/presse/deutsch/pk/2004/mikrozensus_2003i.pdf
150. Stellar E. **The physiology of motivation.** Psychol Rev. 1954 Jan; 61(1):5-22.
151. Ste Marie L, Luquet S, Cole TB, Palmiter RD. **Modulation of neuropeptide y expression in adult mice does not effect feeding.** Proc Natl Acad Sci USA 2005; 102: 18632-18637
152. Strominger JL, Brobeck JR. **A mechanism of regulation of food intake.** Yale J Biol Med. 1953; Apr;25(5): 383-90.
153. Tainter ML, Ludena FP. **Sympathetic chemical transmitters.** Rev Asoc Med Argent. 1950 Jul 15-30 ;64(681-2): 311-6.
154. Varga G, Scarpignato C. **Camostate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists.** Eur J Pharmacol. 1996 Jun 13;306(1-3):153-9.
155. Van Gaal et al. **Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.** Lancet. 2005 Apr 16-22;365(9468):1389-97

156. Vickers SP, Dourish CT and Kennett GA. **Evidence that hypophagic induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT-2C-receptors.** *Neuropharmacology* 2001; 41: 200-209.
157. Voigt JP, Fink H, Marsden CA. **Evidence for the involvement of the 5-HT-1A receptor in CCK induced satiety in rats.,** *Naunyn-Schmiedeberg's Arch. Pharmacol.* 1995; 351: 217-220.
158. Voigt,J.-P., Sohr,R., and Fink,H., **CCK-8S facilitates 5-HT release in the rat hypothalamus.,** *Pharmacol. Biochem. Behav.* 1998; 59: 179-182.
159. Voits M, Förster,S, Rödel S, Voigt J-P, Plagemann A and Fink H. **Obesity induced by unspecific early postnatal overfeeding in male and female rats: hypophagic effect of CCK-8S.** *Naunyn-Schmiedeberg's Arch Pharmacol*, 4 (1996a) 374-378.
160. Voits M., Voigt JP, Boomgaarden M., Henklein P and Fink H. **Comparison of the satiating effect of the CCKA receptor agonist A71378 with CCK-8S.** *Peptides*, 17 (1996b) 355-357.
161. Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM. **Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography.** *Neurosci Lett.* 1988 May 16; 88(1): 11-6.
162. Wang J, Leibowitz KL. **Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats.** *Brain Res.* 1997 Nov 28;777(1-2):231-6.
163. Wangsness M. **Pharmacological treatment of obesity. Past, present, and future.** *Minn Med.* 2000 Nov;83(11):21-6.
164. Weller A, Smith GP, Gibbs J. **Endogenous cholecystokinin reduces feeding in young rats.** *Science.* 1990 Mar 30;247(4950):1589-91.
165. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. **Sibutramine in weight control: a dose-ranging, efficacy study.** *Clin Pharmacol Ther.* 1991 Sep; 50(3): 330-7.

166. WHO. **Obesity: preventing and managing the global epidemic.** WHO Technical Report Series 894, Genf 2000
167. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. **A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine.** Life Sci. 1974 Aug 1; 15(3): 471-9.
168. Woods SC, Seeley RJ. **Adiposity signals and the control of energy homeostasis.** Nutrition 2000; 16(10): 894-902.
169. Woods SC, Schwartz MW, Baskin DG, Seeley RJ. **Food intake and the regulation of body weight.** Annu Rev Psychol 2000; 51: 255-277.
170. Woods SC. **Signals that influence food intake and body weight.** Physiol.and Behavior 2005; 86: 709-16.
171. Yi CX, van der Vliet J, Dai J, Yin G, Ru L, Buijs RM. **Ventromedial arcuate nucleus communicates peripheral metabolic information to the suprachiasmatic nucleus.** Endocrinology. 2006 Jan;147(1):283-94. Epub 2005 Sep 29
172. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. **Positional cloning of the mouse obese gene and its human homologue.** Nature (1994) 372:425-432
173. Zarbin MA, Wamsley JK, Innis RB, Kuhar MJ. **Cholecystokinin receptors: presence and axonal flow in the rat vagus nerve.** Life Sci. 1981 Aug 17; 29(7): 697-705.